Gene Therapy Looks Promising for Transfusion-Dependent β-Thalassemia – Monthly Prescribing Reference
Business Wire (press release) |
Gene Therapy Looks Promising for Transfusion-Dependent β-Thalassemia
Monthly Prescribing Reference A majority of patients with transfusion-dependent β-thalassemia (TDT) were able to achieve freedom from chronic blood transfusion after receiving the gene therapy LentiGlobin (autologous CD34+ cells transduced with the BB305 vector; bluebird bio, Inc … bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical … bluebird bio (BLUE) Highlights NEJM Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM … |
